Minimizing the non-extrapyramidal side-effects of antipsychotics

Acta Psychiatrica Scandinavica

Volumn 94, Issue SUPPL.S389, 1996, Pages 18-24

  Keks, N A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Anticholinergic medication; Antipsychotics: risperidone; Clozapine.side effects; Toxicity, cardiovascular

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE; CHLORPROMAZINE; HALOPERIDOL; OLANZAPINE;

DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; DYSKINESIA; HUMAN; NEUROLOGIC EXAMINATION; PATIENT EDUCATION; REVIEW; SCHIZOPHRENIA; CARDIOTOXICITY; CONFERENCE PAPER; HYPOTENSION; PSYCHOSIS; SEDATION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; HUMANS; NEUROLOGIC EXAMINATION; PATIENT EDUCATION; RISPERIDONE; SCHIZOPHRENIA;

EID: 0030456782     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1996.tb05944.x     Document Type: Article

References (49)

1. Keks NA, Copolov DL, Kulkarni J. Treatment of schizo-phrenia. Med J Aust 1989: 151: 462 467.
2. Gelenberg AJ, Bassuk El, Schoonover SC. The practi-tioner's guide to psychoactive drugs. New York: Plenum, 1991.
3. Kane JM. Schizophrenia. N Engl J Med 1996: 334: 34-41.
4. Casey DE, Keepers GA. Neuroleptic side-effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacol Curr Trends 1988: 5: 74-93.
5. Meltzer HY. Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ, ed. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1277-1286.
6. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side-effects. Acta Psychiatr Scand 1994: 89 (Suppl. 382): 11-15.
7. Awad AG. Quality of life of schizophrenic patients on medication for new drug trials. Hosp Commun Psychiatry 1992: 43: 262-265.
8. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand 1994: 89 (Suppl. 380): 27-32.
9. Rupp A, Keith SJ. The costs of schizophrenia. Psychiatric Clin N Am 1993: 16: 413-423.
10. Vaccaro JV, Young AS, Glynn S. Community-based care of individuals with schizophrenia. Psychiatric Clin N Am 1993: 16: 387-399.
11. Fitton A, Heel RC. Clozapine: a review of its pharmacolo-gical properties and therapeutic use in schizophrenia. Drugs 1990: 40: 722-747.
12. Psychotrophic Drug Guidelines Sub-Committee. Victorian Drug Usage Advisory Committee (i) Schizophrenia and Associated Disorder (ii) Personality Disorders. In: Psychotropic drug guidelines, 3rd edn. Melbourne Victorian Medical Postgraduate Foundation, 1995: 94-106: 148-149.
13. King DJ. Neuroleptics and the treatment of schizophrenia. In: King DJ, ed. Seminars in clinical psychopharmacology. London: Gaskell, 1995: 259-327.
14. Buckley PF, Meltzer HY. Treatment of schizophrenia. In: Schatzberg AF, ed. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press. 1995: 615-639.
15. Umbricht D, Kane JM. Risperidone: efficacy and safety. Schizophr Bull 1995: 21: 593-606.
16. Devinsky O, Honingfeld G, Patin J. Clozapine-induced seizures. Neurology 1991: 41: 369-371.
17. Keks N, Copolov D, Johnson G. Initial Australian experi-ence with the atypical antipsychotic clozapine. Med J Aust 1993: 159: 638-639.
18. Katzung BG. Basic and clinical pharmacology, 6th edn. London: Appleton & Lange, Prentice-Hall, 1995.
19. Memmer MK. Acute orthostatic hypotension. Heart Lung 1988: 17: 134-143.
20. Mathias CJ. Orthostatic hypotension: causes, mechanisms and influencing factors. Neurology 1995: 45 (Suppl. 5): S6-S11.
21. Hopson JR, Rea RF, Kjenzle MG. Alterations in reflex function contributing to syncope: orthostatic hypotension, carotid sinus hypersensitivity and drug-induced dysfunction. Herz 1993: 18: 164-174.
22. Risen SC, Groom GP, Janowsky DS. Interfaces of psycho-pharmacology and cardiology. Part 1. J Clin Psychiatry 1981:42:23-34.
23. Risen SC, Groom GP. Janowsky DS. Interfaces of psycho-pharmacology and cardiology. Part 2. J Clin Psychiatry 1981: 42: 47-59.
24. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995: 21: 579-591.
25. Leysen JE, Janssen PM, Megens AAHP, Scholte A. Risperidone: a novel antipsychotic with balanced serotonin dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994: 55 (Suppl. 5): 5-12.
26. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994: 151: 825-835.
27. Peuskens J and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995: 166: 712-726.
28. Tonkin A, Wing L. Pharmacodynamics and drug action. Clin Pharmacol Ther 1992: 52: 277-285.
29. Mader SL. Aging and postural hypotension an update. J Am Geriatr Soc 1989: 37: 129-137.
30. MacLennan WJ, Ha MRP, Timothy JI. Postural hypoten-sion in old age: is it a disorder of the nervous system or of blood vessels? Age Ageing 1980: 9: 25-32.
31. Van Kammen DP, Marder SR. Dopamine receptor antagonists. In: Kaplan HI, Sadock BJ, ed. Comprehensive textbook of psychiatry, 6th edn. Baltimore: William & Wilkins, 1995: 1987-2022.
32. Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996: 14: 87-96.
33. McElroy SL, Keck PE, Friedman LM. Minimising and managing antidepressant side effects. J Clin Psychiatry 1995: 56 (Suppl. 2): 49-55.
34. Kaplan JI, Sadock BJ. Pocket handbook of psychiatric drug treatment. Baltimore: Williams & Wilkins, 1993.
35. Pollack MH, Rosenbaum JF. Management of antidepress-ant-induced side effects: a practical guide for the clinician. J Clin Psychiatry 1987: 48: 3-8.
36. Keks N, McGrath J, Lambert T et al. The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatr Scand 1994: 90: 358-365.
37. BondolfiG, Baumann P, Dufour H. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. Eur Neuropsychopharmacology 1996: 6: S2-21-25.
38. Lamberti JS. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992: 149: 689-690.
39. Keks NA, Copolov DL, Singh BS. Abnormal prolactin response to haloperidol challenge in men with schizophre-nia. Am J Psychiatry 1987: 144: 1335-1337.
40. Meltzer HY. The mechanism of action of novel antipsych-otic drugs. Schizophr Bull 1991: 17: 263-287.
41. Bitton R, Schneider B. Endocrine, metabolic and nutri-tional effects of psychotrophic drugs. In: Kane JM, Lieberman JA, ed. Adverse effects of psychotropic drugs. New York: Guilford, 1992: 341-355.
42. Copolov DL, Rubin RT. Endocrine disturbances in affect-ive disorders and schizophrenia. In: NemeroffC, Loosen PT, ed. Handbook of clinical psychoneuroendocrinology. New York: Guilford, 1987: 160-194.
43. Cohn JH, Brust J, DiSerio F, Singer J. Effect of bromoc-riptine mesylate on induced hyperprolactinemia in estab-lished psychiatric outpatients undergoing neuroleptic treatment. Neuropsychobiology 1985: 13: 173-179.
44. Matsuoka I, Nakai T, Miyake M, Hirai M, Ikawa G. Effects of bromocriptine in neuroleptic-induced amenor-rhoea, galactorrhea and impotence. Jap J Psychiatry Neurol 1986: 40: 639-646.
45. McEvoy JP. A double-blind crossover comparison of anti-parkinson drug therapy: amantadine vs. anticholinergic in 90. normal volunteers with an emphasis on differential effects on memory function. J Clin Psychiatry 1987: 48 (Suppl. 9): 20-23.
46. Kane J, Honigfeld G, Singer J, Meltzer H. The clozaril collaborative study group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988: 45: 789-796.
47. Alvir JMJ, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994: 55 (Suppl. 9B): 137-138.
48. Zucker S, Zarrabi HM, Schuback WH et al. Chlorpromazine-induced immunopathy: progressive increase in serum IgM. Medicine 1990: 69: 92-100.
49. Chouinard G, Jones B, Remington G et al. A Canadian muticenter placebo-controlled study of fixed doses of risperi-done and haloperidol in the treatment of chronic schizo-phrenic patients. J Clin Psychopharmacology 1993: 13: 25-40.